Rangeley Capital »

Fulcrum Therapeutics shares owned by Rangeley Capital

Quarter-by-quarter ownership of Fulcrum Therapeutics (FULC) shares owned by Rangeley Capital from 13F filings

Historical chart of Rangeley Capital investment in Fulcrum Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Fulcrum Therapeutics held by Rangeley Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fulcrum Therapeutics by Rangeley Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $421k 115k 3.66

More positions owned by Rangeley Capital

Driven Brands Hldgs (DRVN)
Revolution Medicines *w Exp 12/17/202 (RVMDW)
Prothena Corp SHS (PRTA)
Seaport Entmt Group Common Stock (SEG)
Grindr (GRND)
Star Hldgs Shs Ben Int (STHO)
Full House Resorts (FLL)
Arbutus Biopharma (ABUS)
Tripadvisor (TRIP)
Echostar Corp Cl A
Abivax Sa Sponsored Ads (ABVX)
Green Dot Corp Cl A (GDOT)
Lawson Products (DSGR)
Theravance Biopharma (TBPH)
Rallybio Corp (RLYB)

View all positions for Rangeley Capital

Top funds holding Fulcrum Therapeutics

BlackRock
EcoR1 Capital
Tang Capital Management
Nantahala Capital Management
Suvretta Capital Management
D. E. Shaw & Co
Citadel Advisors
Vanguard Capital Management
Jane Street
Adage Capital Partners GP
GSK
Qube Research & Technologies
Renaissance Technologies
ADAR1 Capital Management
State Street Corporation

View all funds holding Fulcrum Therapeutics